| Entry |
|
|---|
| Name |
Ipragliflozin L-proline (JAN);
Suglat (TN) |
|---|
| Formula |
C21H21FO5S. C5H9NO2
|
|---|
| Exact mass |
519.1727
|
|---|
| Mol weight |
519.5823
|
|---|
| Structure |
|
|---|
| Class |
Antidiabetic agent
DG02044 Hypoglycemic agent
DG01794 SGLT2 inhibitor
Metabolizing enzyme substrate
DG02924 UGT substrate
DG03190 UGT2B7 substrate
|
|---|
| Remark |
| Therapeutic category: | 3969 |
| Product (DG01248): | D10200<JP> |
| Product (mixture): | D11064<JP> |
|
|---|
| Efficacy |
Antidiabetic, SGLT-2 inhibitor |
|---|
| Comment |
Phlorizin derivative
|
|---|
| Target |
|
|---|
| Metabolism |
Enzyme: UGT2B7 [HSA: 7364]
|
|---|
| Interaction |
|
|---|
| Structure map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A10 DRUGS USED IN DIABETES
A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10BK Sodium-glucose co-transporter 2 (SGLT2) inhibitors
A10BK05 Ipragliflozin
D10200 Ipragliflozin L-proline (JAN) <JP>
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
396 Antidiabetic agents
3969 Others
D10200 Ipragliflozin L-proline (JAN)
Drug groups [BR:br08330]
Antidiabetic agent
DG02044 Hypoglycemic agent
DG01794 SGLT2 inhibitor
DG01248 Ipragliflozin
D10200 Ipragliflozin L-proline
Metabolizing enzyme substrate
DG02924 UGT substrate
DG03190 UGT2B7 substrate
DG01248 Ipragliflozin
D10200 Ipragliflozin L-proline
Drug classes [BR:br08332]
Antidiabetic agent
DG01794 SGLT2 inhibitor
D10200 Ipragliflozin L-proline
DG02044 Hypoglycemic agent
D10200 Ipragliflozin L-proline
Target-based classification of drugs [BR:br08310]
Transporters
Solute carrier family
SLC5
SLC5A2 (SGLT2)
D10200 Ipragliflozin L-proline (JAN) <JP>
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10200
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10200
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10200
Drug groups [BR:br08330]
Antidiabetic agent
DG02044 Hypoglycemic agent
DG01794 SGLT2 inhibitor
DG01248 Ipragliflozin
Metabolizing enzyme substrate
DG02924 UGT substrate
DG03190 UGT2B7 substrate
DG01248 Ipragliflozin
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 36
1 O2x O 7.7700 -15.5400
2 C1y C 7.7700 -16.9400
3 C1y C 6.5800 -17.6400
4 C1y C 5.3200 -16.9400
5 C1y C 5.3200 -15.5400
6 C1y C 6.5800 -14.8400
7 C1b C 6.5800 -13.3700
8 O1a O 4.1300 -17.6400
9 C8y C 8.9600 -17.6400
10 O1a O 7.7700 -12.6700
11 O1a O 4.1300 -14.8400
12 O1a O 6.5800 -19.0400
13 C8x C 10.1500 -16.9400
14 C8y C 11.4800 -17.6400
15 C8y C 11.4800 -19.0400
16 C8x C 10.2200 -19.7400
17 C8x C 8.9600 -19.0400
18 X F 12.6700 -19.7400
19 C1b C 12.6700 -16.9400
20 C8y C 13.8600 -17.6400
21 S2x S 15.1900 -17.2900
22 C8y C 15.9600 -18.4100
23 C8y C 15.1200 -19.4600
24 C8x C 13.8600 -18.9700
25 C8x C 17.3600 -18.6200
26 C8x C 17.8500 -19.9500
27 C8x C 17.0100 -21.0000
28 C8x C 15.6100 -20.7900
29 C1x C 20.6500 -17.7100
30 C1x C 21.0700 -19.0400
31 C1x C 22.4700 -19.0400
32 C1y C 22.8900 -17.7100
33 N1x N 21.7700 -16.8700
34 C6a C 24.0800 -17.0100
35 O6a O 25.2700 -17.7100
36 O6a O 24.0800 -15.6100
BOND 39
1 1 2 1
2 2 3 1
3 3 4 1
4 4 5 1
5 5 6 1
6 1 6 1
7 6 7 1 #Up
8 4 8 1 #Up
9 2 9 1 #Up
10 7 10 1
11 5 11 1 #Down
12 3 12 1 #Down
13 9 13 2
14 13 14 1
15 14 15 2
16 15 16 1
17 16 17 2
18 9 17 1
19 15 18 1
20 14 19 1
21 19 20 1
22 20 21 1
23 21 22 1
24 22 23 1
25 23 24 1
26 20 24 2
27 22 25 2
28 25 26 1
29 26 27 2
30 27 28 1
31 23 28 2
32 29 30 1
33 30 31 1
34 31 32 1
35 32 33 1
36 29 33 1
37 34 35 1
38 32 34 1 #Down
39 34 36 2
|
|---|
